Condition: Clostridioides Difficile Infection · Recurrent Infection · Sponsor: Hospices Civils de Lyon
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors. Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI. In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes. Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical ef…
This description comes directly from the study's public registry record.
Nicolas BENECH, MD · 04 26 10 94 35 · nicolas.benech@chu-lyon.fr
Fanny JOUBERT · 04 26 73 27 27 · Fanny.joubert@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| CH Annecy Genevois Service de Maladies infectieuses | Annecy, France | Not Yet Recruiting |
| Service d'hépato-gastroentérologie - CHU Estaing | Clermont-Ferrand, France | Recruiting |
| CHU Grenoble Service Maladies infectieuses et tropicales | Grenoble, France | Not Yet Recruiting |
| CHU Lille Unité des Maladies Infectieuses et tropicales | Lille, France | Not Yet Recruiting |
| Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse | Lyon, France | Recruiting |
| APHM La Timone Service de Maladies infectieuses | Marseille, France | Recruiting |
| Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP) | Paris, France | Recruiting |
| Service d'infectiologie - Hôpital Nord / CHU Saint Etienne | Saint-Etienne, France | Recruiting |
| Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse | Toulouse, France | Recruiting |
| Service de Maladies Infectieuses - CH de Valence | Valence, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06306014